HHS Unveils Key Dates for Medicare Drug Price Negotiations

March 6, 2023 by TWN Staff
HHS Unveils Key Dates for Medicare Drug Price Negotiations
(Photo by Sarcifilippo via Pixabay)

WASHINGTON — When the Inflation Reduction Act became law last year, it empowered the Health and Human Services secretary, for the first time ever, to begin negotiating certain prescription drug prices with drug manufacturers. The prices would go into effect in 2026.

On Monday, both the Centers for Medicare & Medicaid Services and the Department of Health and Human Services announced key dates in the process they contend will lower prescription drug prices for millions of seniors and people with disabilities across the country.

The biggest difference in the timelines is the CMS memo details multiple comment opportunities for members of the public, people with Medicare and consumer advocates, pharmaceutical manufacturers, Medicare Advantage and Part D plans, health care providers and pharmacies, and other interested parties.

“We cannot do this important work alone and will engage with the public early and often,” CMS Administrator Chiquita Brooks-LaSure offered by way of explanation. 

“We are proactively seeking feedback and insights from a broad range of interested parties throughout implementation of this historic law,” she said.

Key dates for implementation include:

  • By Sept. 1, 2023, CMS will publish the first 10 Medicare Part D drugs selected for the Medicare Drug Price Negotiation Program.
  • The negotiated maximum fair prices for these drugs will be announced by Sept. 1, 2024, and prices will be in effect starting Jan. 1, 2026.
  • In future years, CMS will select for negotiation 15 more Part D drugs for 2027, 15 more Part B or Part D drugs for 2028, and 20 more Part B or Part D drugs for each year after that, as outlined in the Inflation Reduction Act.

“Public feedback is critical to our ability to successfully implement this law and ensure access to innovative, affordable therapies and treatments,” said Dr. Meena Seshamani, M.D., Ph.D., CMS deputy administrator and director of the Center for Medicare. “Through this detailed timeline, we offer stakeholders the predictability they need to contribute to our implementation efforts. We want the public to know when and how they can make their voices heard on forthcoming policies.”

Provisions of the Inflation Reduction Act already in effect:

  • Free vaccines: Recommended preventive vaccines are free of charge for people with Medicare prescription drug coverage as of Jan. 1, 2023. Most notably, these vaccines include shingles and Tdap. This will provide significant savings for people enrolled in Medicare prescription drug plans, as the shingles vaccine alone can cost up to a few hundred dollars. 
  • Insulin cap: Cost-sharing for a month’s supply of each covered insulin is capped at $35 and there is no deductible for these products for people with Medicare prescription drug coverage as of Jan. 1, 2023. More than a million Medicare beneficiaries with diabetes will benefit from this $35 cost-sharing cap per month’s supply of each covered insulin.
    Currently, nearly a quarter of Medicare beneficiaries taking insulin spend more than $70 a month on insulin.  
  • Rebates required from drug manufacturers’ increasing prices faster than inflation. Manufacturers will need to pay rebates to Medicare if they increase their prices for certain drugs at a rate that exceeds the rate of inflation. The first rebate period began Oct. 1, 2022, in Part D and Jan. 1, 2023, in Part B.
  • ACA subsidies: During Marketplace Open Enrollment this year, more people will qualify for help purchasing affordable high-quality health coverage.  
  • Biosimilars: On Oct.1, 2022, CMS implemented the Medicare Part B payment changes, for certain qualifying biosimilars, to temporarily increase payment to providers who administer these products, in order to encourage price competition and the use of biosimilars and their reference biological products.

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference biological product. Many biosimilars are life-saving medicines that treat conditions such as diabetes, cancer and immune disorders.

The goal of this provision is to increase access to biosimilars, as well as to encourage competition between biosimilars and reference biological products, which may, over time, lower drug costs and lead to savings for beneficiaries and Medicare.

The more detailed CMS timeline can be found here.

A+
a-
  • Inflation Reduction Act
  • Medicaid
  • Medicare
  • prescription drug prices
  • In The News

    Health

    Voting

    Medicare

    March 10, 2025
    by Dan McCue
    House Democrats Demand Answers Regarding CMS Firings

    WASHINGTON — A group of leading Democrats, including Rep. Frank Pallone Jr., D-N.J., and Richard Neal, D-Mass., are demanding answers... Read More

    WASHINGTON — A group of leading Democrats, including Rep. Frank Pallone Jr., D-N.J., and Richard Neal, D-Mass., are demanding answers from the acting administrator of the Centers for Medicare and Medicaid Services about the recent purge of employees at the agency. Pallone, ranking member of the... Read More

    Senate Republicans Approve Budget Framework After All-Night Vote

    WASHINGTON (AP) — Republican senators pushed a $340 billion budget framework to passage early Friday, chugging through an all-night session and Democratic... Read More

    WASHINGTON (AP) — Republican senators pushed a $340 billion budget framework to passage early Friday, chugging through an all-night session and Democratic opposition in a step toward unleashing money the Trump administration says it needs for mass deportations and border security that top their agenda. The hours-long “vote-a-rama” rambled along in a... Read More

    Treasury Watchdog Begins Audit of Musk DOGE Team's Access to Federal Government's Payment System

    WASHINGTON (AP) — The Treasury Department's Office of Inspector General on Friday said it was launching an audit of the... Read More

    WASHINGTON (AP) — The Treasury Department's Office of Inspector General on Friday said it was launching an audit of the security controls for the federal government's payment system, after Democratic senators raised red flags about the access provided to Trump aide Elon Musk's Department of Government Efficiency team.... Read More

    January 29, 2025
    by Tom Ramstack
    Kennedy Downplays Vaccine Statements During Health Dept. Confirmation Hearing

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate... Read More

    WASHINGTON — Robert F. Kennedy Jr. tried to deflect accusations of being a junk science advocate Wednesday during his Senate confirmation hearing to become secretary of the U.S. Department of Health and Human Services. Much of his time was spent defending his previous statements against vaccines... Read More

    December 10, 2024
    by Dan McCue
    Senate Panel Scrutinizes Medicare Advantage Denials of Prior Authorization Requests

    WASHINGTON — The nation’s largest Medicare Advantage insurers have been boosting their profits by denying prior authorization requests for post-acute... Read More

    WASHINGTON — The nation’s largest Medicare Advantage insurers have been boosting their profits by denying prior authorization requests for post-acute care, such as stays in a nursing facility, at far higher rates than they did for other types of care, a report from a Senate investigative... Read More

    November 19, 2024
    by Dan McCue
    Trump Taps ‘Dr. Oz’ to Oversee Medicare, Medicaid

    WASHINGTON — President-elect Donald Trump has asked Dr. Mehmet Oz, the celebrity surgeon who for years was a fixture on... Read More

    WASHINGTON — President-elect Donald Trump has asked Dr. Mehmet Oz, the celebrity surgeon who for years was a fixture on daytime TV, to be the next administrator of the Centers for Medicare and Medicaid Services. “America is facing a Healthcare Crisis, and there may be no... Read More

    News From The Well
    scroll top